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  The clinical effects of estramustine phosphate on prostatic cancer were evaluated in ten patients．
  Seven patients of them were adrninistered with estramustine phospha亡e as primary treatment
（group A） and the others had been previously treated with anti－androgen treatment with unsatisfactory
results （group B）．
  The clinical effects were judged froni improvement of objective and／or subjective syinptonis．
  The clinical responses were observed in 6 of the 7 patients in group A， and 2 of the 3 patients in
group B．
  Side effects were observed in 4 patients． Wc noticed gastrolntestinal disturbances， hepatic負皿ction
abnormal， gynecomastia and chest pain as side effects．
  We concluded from this clinical trial that， oral estramustine phosphate showed good clinical


































 estramustine phosphateとして140 mg含有する
Table L臨床成績
       投与量症例緬 年齢 進行度     期間
        captd
           局所
排尿
  頻尿．終痛残尿量大きさ 硬さ
困難
尿道レ酸アオス      総合
       副作用     備考線像ファターゼ     判定
   1
   2
   3
   4
A群
   5
   6
  ’7
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B群   10
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73 C 4 10M ±． ±
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※  胸苦しさ
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   1年3ヵ月前
やや   Cast．
有効 ホンパン
    抵抗性
   3年6ヵ月前
    Cast・無効   ホンバン
    抵抗性
  2年前Cast．やや  ホンバン有効    抵抗性















































































残尿量  触診所見  尿道レ線像  酸フォスファターゼ
改  善  6
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